Why Can a Molecule of Just ~31 Amino Acids Reshape Modern Pharma? Reading the Next Blockbuster Through the Chemical Design of Semaglutide

An article that reads an industry through its molecules. This is an industry-and-chemistry analysis, not medical advice or dosing guidance; all indications, trial data, and approval statuses below are objective statements of public regulatory and literature information, with primary sources cited where possible.

In one sentence: GLP-1 began as a single incretin hormone in a physiology textbook; today nearly every major pharmaceutical company runs its own GLP-1 program. What makes it so coveted is not the single selling point of "weight loss," but its platform property — one class of molecule can extend across diabetes, obesity, cardiovascular, kidney, and liver indications. And for the chemical industry, its deeper significance is this: it pulled an entire technology chain — protected amino acids, coupling reagents, solid-phase peptide synthesis, purification, and scale-up manufacturing — into the industrial center of gravity all at once.

A Rare Case of an Entire Industry Entering at Once

Over the past decade, few mechanisms of action have drawn nearly every large pharmaceutical company into the same race at the same time. From Novo Nordisk to Eli Lilly, from Pfizer and Amgen to Roche, AstraZeneca, and Boehringer Ingelheim, to newcomers like Structure Therapeutics — almost every one is advancing its own GLP-1 or multi-target metabolic program.

This is not an ordinary new-drug contest but a whole-industry scramble that simultaneously touches metabolic disease, cardiovascular disease, and a widening set of indications. Why GLP-1, of all things? The answer isn't in marketing; it's in two properties of this class of molecule: biologically it can do an unusual amount, and chemically it is unusually hard to make.

2. What Is GLP-1, Really?

GLP-1 (glucagon-like peptide-1) is not a drug but a naturally occurring incretin hormone. After a meal it participates in promoting insulin release, suppressing glucagon, slowing gastric emptying, and acting centrally to produce satiety.

But native GLP-1 has a fatal engineering flaw: in the body it is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4), which cleaves a dipeptide from its N-terminus, giving it a plasma half-life of only about 2 minutes before rapid renal clearance. So what pharma actually does is not "supplement GLP-1," but design molecules that can mimic GLP-1's action durably and stably. Turning a two-minute signal into a drug that lasts a week is the chemical starting point for all of this.

3. A Timeline: From Gut Hormone to Blockbuster

To understand GLP-1's position today, it helps to trace the path it took (approval years below are each drug's first US FDA approval):

1980s     GLP-1 identified as an incretin hormone
   │
2005      Exenatide (Byetta) — first GLP-1 drug approved
   │
2010      Liraglutide (Victoza) — once daily
   │
2017      Semaglutide (Ozempic) — once weekly
   │
2022      Tirzepatide (Mounjaro) — dual GLP-1/GIP
   │
2026      Orforglipron (Foundayo) — first oral small-molecule GLP-1
   │
Future    Multi-target, oral, and route-of-administration competition

In barely twenty years, this thread grew from a physiological observation into one of the most investment-intensive races in global pharma.

4. What Really Draws Big Pharma: Platform Property, Plus "De-Risked R&D"

If it were only a weight-loss drug, it wouldn't pull an entire industry in. The real attraction has two layers.

The first is the platform-drug property — one validated molecular scaffold that can extend across a set of related metabolic indications. Take semaglutide: public regulatory information shows a clear trajectory of expansion — first approved for type 2 diabetes (Ozempic), then obesity / weight management (Wegovy); in 2024, approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity; in January 2025, based on the FLOW trial, approved to reduce the risk of kidney-disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease; in August 2025, based on the ESSENCE trial, becoming the first GLP-1-class drug approved for MASH (metabolic dysfunction-associated steatohepatitis) with fibrosis (all per FDA and Novo Nordisk public announcements). These are objective statements of regulatory approval, not this article's endorsement or efficacy assessment of any use — but to an industry observer, the trajectory itself makes the point: GLP-1 is no longer a diabetes drug; it is a continually expanding metabolic-disease platform. The core molecule is developed once, and each new indication is an incremental extension on the same asset rather than a start from zero — precisely what the old "one blockbuster, one disease" model lacked.

The second layer, and the more decisive one in the investment logic: GLP-1 dramatically lowered R&D risk. What pharma fears most is a Phase III failure — a mechanism that doesn't hold, a target that doesn't work, safety that doesn't clear. But for the GLP-1 pathway, mechanism, target, and safety have all been validated repeatedly. That means a later entrant developing a new molecule is no longer betting on "does it work at all," but on "can we do it better." For large pharma and venture capital alike, this is a rare kind of race in which the front-loaded risk has been sharply cut — and that is the real commercial rationale behind an entire industry entering at once.

5. Why Is It So Hard to Make? GLP-1 Is First a Medicinal-Chemistry Problem

This is the true core of the article, and a layer rarely explained well elsewhere.

Start with an easily overlooked fact: native GLP-1 is essentially undruggable as-is. It inactivates and clears within two minutes of entering the body — a signaling molecule that only lasts two minutes, however effective, cannot become a drug taken daily or weekly. The hard part was never discovering GLP-1; it was redesigning a natural signaling molecule into something that can be manufactured, stored, shipped, and produced at scale. So the real question, from the very beginning, was never "should we use GLP-1," but "how do we turn a two-minute molecule into a drug that lasts days." Most mainstream GLP-1 drugs today are not conventional small-molecule APIs but precisely engineered long-acting peptides — and their barrier is set at the molecular-design stage.

Step one: make the molecule live long enough. Native GLP-1 lasts only two minutes because DPP-4 cleaves a dipeptide from its N-terminus. The fix? Nature gave a hint first: exenatide derives from exendin-4 in the saliva of the Gila monster, whose corresponding N-terminal position is naturally a glycine rather than an alanine, making it inherently DPP-4-resistant. Semaglutide took the "precise engineering" route — per its discovery paper (Lau et al., J. Med. Chem. 2015), it differs from native GLP-1 by only two amino-acid substitutions: α-aminoisobutyric acid (Aib) replacing the alanine at position 8 to resist DPP-4 cleavage, plus an Arg34 substitution.

Step two: make the molecule clear slowly enough — this is a pharmacokinetics design problem. Enzyme resistance alone isn't enough; a low-molecular-weight peptide is still rapidly filtered and cleared by the kidney. Semaglutide's solution is to attach, at the side chain of lysine 26, via a γ-glutamate linker and two AEEA spacers, a C18 fatty diacid chain (Lau et al., 2015). This fatty chain lets the molecule bind non-covalently and with high affinity to plasma albumin — in effect giving the peptide a "macromolecular shell": enlarging its hydrodynamic radius, evading glomerular filtration, and dodging enzymatic degradation, forming a slow-release depot in circulation. The result: half-life extends from about 2 minutes to about 7 days, making once-weekly dosing possible. The chain length wasn't picked at random either: Lau et al. systematically compared C14, C16, C18, and C20 diacids — shorter ones bind albumin too weakly, longer ones lose water solubility, and C18 is the balance point that structure–activity relationship (SAR) work landed on. Worth spelling out one layer here: what medicinal chemistry truly optimizes at this step is not just receptor affinity, but the whole pharmacokinetic (PK) behavior — absorption, distribution, metabolism, clearance. Semaglutide's real invention lies not in "which amino acids," but in this enzyme-resistant + albumin-anchored PK engineering.

Step three: actually make it — the real constraints of solid-phase synthesis. Semaglutide's peptide backbone has about 31 amino acids; tirzepatide has 39. Such peptides are made mainly by solid-phase peptide synthesis (SPPS): the chain is built one amino acid at a time on a resin, each residue a "deprotection–coupling" cycle, so one chain often needs 30 to 40 or more coupling cycles. At 31–39 amino acids these are among the more complex long-chain peptides in commercial SPPS — SPPS itself can go longer (dozens of residues and beyond), but as chain length grows, cumulative side reactions and purification difficulty rise sharply. As an aside, that albumin-binding side chain is usually synthesized as a separate "building block" bearing an activated succinimidyl ester (OSu) at its end, then coupled to the chain — and activating reagents of the Fmoc-OSu type are common items in the peptide-reagent layer.

Here lies a question often asked but rarely answered: why ~31 amino acids? Semaglutide's ~31-residue backbone is not the pursuit of some fixed length; it is the outcome of long SAR and pharmacokinetic optimization while preserving GLP-1 biological activity — and at the same time, this length keeps manufacturing complexity within a commercially acceptable range. In other words, chain length isn't the design goal but the landing point of a trade-off among activity, stability, and manufacturability. Every choice in molecular design is ultimately paid for on the synthesis floor.

The price: staggering material intensity. An authoritative review from the ACS Green Chemistry Institute Pharmaceutical Roundtable (Isidro-Llobet et al., J. Org. Chem. 2019) estimates that for peptides of molecular weight 1,000–5,000 Da, the Process Mass Intensity (PMI) typically runs between 3,000 and 15,000 kg of material per kg of product — with washes and solvents making up the vast majority of the waste. This is why scaling a peptide is never simply "run the reaction bigger."

6. Why Capacity Is the Bottleneck, and Only a Few Players Can Do It

Once the manufacturing difficulty is clear, so is why the GLP-1 surge is driving a rare wave of upstream capacity expansion — GLP-1 is not a product but an entire supply chain:

          GLP-1 drug (finished)
                 ▲
           Fill / injection pen
                 ▲
           Lyophilization
                 ▲
           Purification (prep HPLC)
                 ▲
       Solid-phase peptide synthesis (SPPS)
                 ▲
   Coupling reagents ─┐        ┌─ Resin
                      ▼        ▼
          Protected amino acids (Fmoc amino acids)

On capacity, leading peptide CDMOs are committing rarely seen capital: per public announcements, CordenPharma has announced a peptide strategic investment exceeding €1 billion, adding tens of thousands of liters of solid-phase synthesis capacity; Axplora is investing in France to build large-scale HPLC and continuous-chromatography purification, specifically to support peptide purification including GLP-1. (These are companies' publicly disclosed investment intentions; exact scale and timing are per their official announcements.)

But what truly determines "who can do it" is often not the synthesis itself, but every step after it: prep-scale HPLC purification, lyophilization, aseptic fill, and regulatory compliance — a commercial peptide must cross dozens of consecutive process steps, and each step's yield multiplies. Even with high individual step yields, compounded over dozens of steps the overall yield and consistency remain a very high bar. And for commercial production, the real challenge is often not completing the first synthesis, but achieving consistent purity, impurity profile, and yield across many consecutive batches while satisfying regulators — this is the hardest gap, between "can make it" and "can keep supplying it." Add the supply concentration and lead-time volatility of key inputs like protected amino acids, resins, and coupling reagents (multiple industry analyses cite protected amino acids as the hidden bottleneck to scale), and the companies that can deliver ton-scale GLP-1 peptide stably, compliantly, and on time are naturally few. This is also where the GLP-1 boom connects most directly to chemical supply: it pulls not just finished drug, but that entire "invisible" upstream layer of Fmoc-protected amino acids, coupling reagents (such as HATU, HBTU), activated building blocks, and chromatography media.

7. From Single to Multi-Target: The Molecular Arms Race

Competition in GLP-1 shifted long ago from "make a GLP-1" to "make a better GLP-1." The rough thread of technical evolution: from once-weekly semaglutide, to Lilly's tirzepatide — a dual-target molecule agonizing both GLP-1 and GIP receptors; to the investigational retatrutide — a triple-target molecule acting on GLP-1, GIP, and glucagon receptors. In its Phase 2 obesity trial (Jastreboff et al., NEJM 2023, REMD-003, n=338), the highest-dose 12 mg group showed a mean 24.2% weight reduction at 48 weeks, the largest reported for an anti-obesity drug at the time, with the Phase 3 TRIUMPH trial underway (this is a specific trial's reported result, not a general promise). In addition, investigational molecules such as Novo Nordisk's amycretin attempt to integrate GLP-1 and amylin activity into a single molecule.

Worth noting: the point of multi-target design is not merely to push weight loss higher, but to seek a new balance among glucose control, energy metabolism, fat metabolism, and long-term tolerability — the direction of competition is shifting from "stronger" toward "more balanced."

8. The Next Contest: Oral, Small Molecule, and Route of Administration

The next round of competition likely won't be only between Novo and Lilly, nor only about "whose peptide is stronger." One variable reshaping the field is route of administration and molecule type.

The most representative case is Lilly's orforglipron — not a peptide, but an oral small-molecule, non-peptide GLP-1 receptor agonist, approved by the FDA on April 1, 2026 (brand name Foundayo, per Lilly's announcement) for adults with obesity or overweight with related conditions. This is pivotal: it means the impression that "GLP-1 drugs are almost all peptides" is being broken. Once the small-molecule oral route matures, its industrial logic is entirely different from peptides — because small molecules do not depend on the whole SPPS capacity-and-supply-chain apparatus, and cost, capacity, and dosing convenience could all be rewritten.

In other words, GLP-1's next contest is a multi-dimensional competition among peptide vs. small-molecule routes, injection vs. oral, and efficacy vs. accessibility — no longer a single-dimensional "who is stronger."

ChemAbout Insight

Twenty years ago, GLP-1 was just an incretin hormone in a physiology textbook. Its path to today's race is, in fact, an accumulation of concrete chemical decisions: swapping one amino acid for Aib to dodge an enzyme; hanging a C18 fatty chain to borrow plasma albumin; stopping the chain at about 31 amino acids to match the reality of synthesis — each a trade-off among receptor activity, stability, and manufacturability. It is precisely these seemingly minor molecular choices that ultimately decide whether a drug can be dosed once a week, whether it can extend to the next indication, whether it can be made at scale.

Today it looks like a commercial contest over weight-loss drugs; but from a medicinal-chemistry view, what it really proves is something else: when a molecule's structural design is successful enough, what it changes is not just one indication, but the resource allocation of an entire supply chain — from basic research, process development, and raw-material supply, to manufacturing capability, capital deployment, and regulatory strategy, all reorganizing around this class of molecule. What truly reshapes an industry has never been the market — it is the molecule itself.

And for medicinal chemistry, semaglutide's real innovation may not be making GLP-1 more complex, but giving a signaling molecule that naturally exists for only about two minutes, for the first time, the ability to persist as an industrial drug.

A note: finished GLP-1-class drugs are patent-protected prescription medicines, outside the tradeable scope of a chemical marketplace. What is related and can be traded compliantly is the upstream peptide-reagent layer — coupling and activating reagents such as Fmoc-OSu and HATU. ChemAbout provides structured compound information and supplier listings for this reagent layer.

---

Evidence Notes

Key Facts

• Biology: GLP-1 is an incretin hormone (insulinotropic, glucagon-suppressing, gastric-emptying-slowing, satiety) rapidly inactivated by DPP-4 — physiology texts and GLP-1 pharmacology reviews.
• Medicinal chemistry: Lau, J. et al. J. Med. Chem. 2015, 58(18):7370-7380 (Aib8/Arg34 substitutions, Lys26 acylation, C14-C20 diacid comparison, albumin-binding design); Isidro-Llobet, A. et al. J. Org. Chem. 2019, 84(8):4615-4628 (ACS GCIPR; peptide PMI 3,000-15,000 kg/kg).
• Clinical: Jastreboff, A. M. et al. NEJM 2023 (retatrutide Phase 2, REMD-003, n=338; 12 mg / 48 weeks, 24.2% weight reduction).

Industrial Map

• Peptide manufacturing chain: protected amino acids -> resin + coupling reagents -> solid-phase peptide synthesis (SPPS) -> prep-HPLC purification -> lyophilization -> fill / injection pen.
• SPPS coupling cycles, 31/39-amino-acid chain length, and purification as the throughput bottleneck — Drug Discovery News and industry reporting.

Regulatory Status

• Ozempic (semaglutide) CKD/cardiovascular indication, FDA/Novo Nordisk, 2025-01 (FLOW).
• semaglutide for MASH with fibrosis, FDA/Novo Nordisk, 2025-08 (ESSENCE).
• Foundayo (orforglipron), FDA approval for obesity/overweight, Lilly, 2026-04-01.

Supply Chain Notes

• CDMO peptide-capacity expansion (CordenPharma, Axplora) per company public announcements; supply concentration of protected amino acids / resins / coupling reagents is industry analysis, cited as a qualitative trend with no unsourced specific figures.

Sources & Method

• Grading: primary literature, regulatory documents, and peer-reviewed journals take priority; industry and market figures are labeled as third-party estimates, not asserted as fact. Pipeline and indication statuses change over time; figures are as of the points noted in the text, and current regulator/company announcements govern.